Lenalidomide Orion

Lenalidomide, the active ingredient in Lenalidomide Orion, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It treats multiple myeloma and myelodysplastic syndromes with del(5q) chromosome abnormality in adult patients.

GNH USA supplies Lenalidomide Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related cytogenetic disorders, acting on malignant plasma cells and abnormal bone‑marrow clones.

Multiple Myeloma: improves response rates and prolongs progression‑free survival in newly diagnosed or relapsed disease. Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and improves peripheral blood counts. Relapsed/Refractory Multiple Myeloma: provides an additional therapeutic option after prior lines of therapy.

Common Side Effects: - Neutropenia: reduced neutrophil count, increasing infection risk. - Thrombocytopenia: lowered platelet levels, may cause bruising. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools, sometimes accompanied by abdominal cramping.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia or thrombocytopenia: may require treatment interruption. - Secondary primary malignancies: emergence of new cancers. - Embryo‑fetal toxicity: high risk of birth defects if exposure occurs during pregnancy.

Lenalidomide requires careful monitoring and specific safety measures. - Pregnancy contraindication: avoid use in pregnant women; teratogenic risk is category X. - Thromboembolic risk: assess need for prophylactic anticoagulation in high‑risk patients. - Hematologic monitoring: regular CBC checks to detect neutropenia or thrombocytopenia. - Renal impairment: evaluate kidney function before initiating therapy. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Potent CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - P‑glycoprotein substrates (e.g., digoxin): possible altered levels. - Immunosuppressants (e.g., cyclosporine): increased risk of infection. - Vaccines (live attenuated): reduced vaccine effectiveness.